导读： 近日，新疆大学发布多批政府采购意向，仪器信息网特对其中的仪器设备品目进行梳理，统计出1项仪器设备采购意向，预算 总额达1.20亿元。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近 日 ， 新 疆 大 学 发 布 1 项 仪 器 设 备 采 购 意 向 ， 预 算 总 额 达 1.20 亿 元 ， 涉 及 147 台 （ 套 ） 仪 器 设 备 ， 预 计 采 购 时 间 为 2025年4月。 新疆大学 202 5 年 4 月仪器设备采购 意向汇总表 | | | | 采 | | --- | --- | --- | --- | | 采购 | 需求 | 预算 | 购 | | 项目 | 概况 | 万元 | 时 | | | | | 间 | | | 采购标的名称：新疆大学公共科研平台2024年重大设备更新项 | | | | | 目采购标的数量：147 采购需求功能或目标：新疆大学公共科 | | | | 公共 | 研平台2024年重大设备更新项目，项目主要为教学科研专用仪 | | | | 科研 | 器设备、进口科研教学仪器设备、专用（通用） ...

Core Viewpoint - The "Science Intelligence White Paper 2025" emphasizes the integration of AI in scientific instruments, transforming them from mere data collection tools to intelligent research partners, enhancing efficiency and capabilities across various scientific fields [1][4][5]. Group 1: Integration of AI in Scientific Instruments - The white paper highlights the deep integration of scientific intelligence (AI for Science, AI4S) with scientific instruments, showcasing how AI empowers traditional instruments to become intelligent research partners [5]. - AI-driven automation in experiments has shown significant improvements, such as a 30% increase in stability and a 50% boost in data collection efficiency in nuclear fusion research [5][6]. - In drug development, automated laboratories utilizing AI algorithms can complete thousands of compound screenings within 48 hours, achieving speeds 10 times faster than traditional methods [6]. Group 2: Trends in Scientific Instrument Intelligence - The design philosophy of scientific instruments is undergoing three major transformations: - Human-machine interaction revolution, with 90% of new instruments featuring smart interfaces, including gesture control [11]. - Integrated data management and analysis, allowing instruments to generate visual reports directly, such as automatic mutation annotation in gene sequencers [13]. - Sustainable design, with 60% of instruments expected to use bio-based resins or recycled metals [15]. Group 3: Global Competitive Landscape and China's Breakthroughs - China is leading in specific fields such as Earth and environmental sciences, with advancements in AI meteorological models and remote sensing instruments [17]. - The domestic production rate of online detection instruments in intelligent manufacturing has surpassed 60% [18]. - However, there are challenges, including a reliance on imports for high-end analytical instruments, with over 80% of such instruments being imported [19]. Group 4: Future Outlook for Scientific Instruments - The future of scientific instruments is projected to focus on three main directions: - Intelligent upgrades, with AI deeply embedded in instrument control and data analysis processes [23]. - Development of specialized instruments for extreme environments, such as deep-sea and space applications [24]. - Establishing an open ecosystem through global laboratory alliances to share material databases [25].

Core Viewpoint - The article discusses the recent decision by the FCC to prohibit Chinese laboratories deemed a national security risk from testing electronic devices exported to the U.S., including smartphones and other wireless devices [1][3]. Group 1: New Regulations - The FCC unanimously passed a new rule aimed at preventing entities with state-owned backgrounds or other untrustworthy actors from controlling the U.S. wireless device authorization process [3]. - The regulations will ensure that hundreds of testing laboratories and telecom certification bodies do not have ownership interests that pose national security risks, including being influenced by foreign adversaries [3]. Group 2: Scope of the Rule - All electronic devices that emit radio frequencies, such as IoT devices, computers, fitness trackers, network equipment, smartphones, and baby monitors, must obtain authorization for use in the U.S. [3].

Core Viewpoint - Zhenmai Bio has successfully completed a C+ round financing of 280 million yuan, aiming to enhance its commercialization ecosystem and global expansion strategy, thereby accelerating domestic substitution and technological breakthroughs abroad [1][3]. Financing and Strategic Goals - The financing round was led by multiple investors including Shengxiang Bio, Jinyu Medical, and others, which will provide sufficient momentum for market consolidation, capacity expansion, and compliance layout [1]. - The funds will support Zhenmai Bio's strategic goals of commercial ecosystem construction and global expansion [1]. Product Development and Achievements - Zhenmai Bio has launched two flagship products: the SURFSeq 5000, which has the highest global throughput of 2.2 Tb/run, and the SURFSeq Q, which boasts a daily output of 9 Tb, both receiving high recognition from users [2]. - The company has received regulatory approval for two significant medical devices, marking a milestone in domestic high-throughput sequencing technology [2]. Market Expansion and Partnerships - Zhenmai Bio's global business has expanded to over 50 countries and regions, with nearly 500 substantial partnerships, including top research institutions and clinical medical organizations [3]. - The company aims to strengthen its industry advantages and accelerate its position as a global leader in gene sequencing and life omics [3]. Leadership and Investor Insights - The chairman of Zhenmai Bio expressed gratitude for the support from shareholders, emphasizing the strategic resonance between capital, innovation, and industry chains [4]. - Investors highlighted Zhenmai Bio's strong capabilities in sequencing technology and its potential for international breakthroughs, indicating a commitment to deepening collaboration in precision medical technology [5][6].

Core Viewpoint - The CRISPR-TO technology enables precise spatial regulation of endogenous RNA, providing a new tool for studying RNA functions and related diseases [1][2]. Group 1: Technology Overview - CRISPR-TO utilizes the Class II Type VI CRISPR-Cas13 system for spatial transcriptome regulation, allowing for targeted RNA manipulation without altering genetic sequences [3][4]. - The technology combines dCas13 with signaling peptides or motor proteins through a heterodimerization mechanism, facilitating both passive diffusion and active transport of RNA [3][4]. Group 2: Applications and Findings - CRISPR-TO successfully targets endogenous RNA to various subcellular compartments, including mitochondria, P-bodies, stress granules, telomeres, and nuclear stress bodies, enabling real-time observation of RNA dynamics in live cells [4][5]. - Targeting mRNA to P-bodies significantly reduced its degradation rate and extended its half-life, supporting the theory that P-bodies primarily serve as mRNA storage sites rather than degradation sites [4]. Group 3: Research Breakthroughs - The technology demonstrated the capability for long-distance transport of endogenous mRNA (approximately 1 mm) in primary mouse cortical neurons, allowing for the study of mRNA's cooperative effects [5][8]. - High-throughput screening using CRISPR-TO revealed that targeting Stmn2 mRNA to neurites promotes rapid neurite growth, linking it to microtubule dynamics and potential implications for ALS [8][9]. Group 4: Future Implications - CRISPR-TO bridges gaps left by existing sequencing and imaging technologies, offering a high-throughput platform for systematic studies of spatial transcriptome functions across various biological systems and disease contexts [9].

Core Insights - Xi'an Jiaotong University has announced procurement intentions for 23 items of scientific instruments, with a total budget of 113 million yuan [1][2] Procurement Summary - The procurement includes advanced instruments such as: - Raman imaging-scanning electron microscope system, budgeted at 9 million yuan - High-energy X-ray computed tomography system, budgeted at 5.23 million yuan - Liquid chromatography-inductively coupled plasma mass spectrometry system, budgeted at 1.8 million yuan - Small animal in vivo imaging system, budgeted at 3.5 million yuan - Electronic direct detection system, budgeted at 8.08 million yuan - The expected procurement period is from April to June 2025 [2][4][5] Instrument Functions - The instruments serve various advanced research functions: - The electron paramagnetic resonance spectrometer provides insights into the structure and dynamics of materials with unpaired electrons [4] - The high-energy X-ray computed tomography system enables non-destructive 3D imaging of large and high-density samples [4] - The liquid chromatography-inductively coupled plasma mass spectrometry system allows for quantitative and qualitative analysis of inorganic elements [4] - The small animal imaging system monitors the distribution and metabolism of drugs within living organisms [4] - The electronic direct detection system enhances imaging capabilities at the atomic scale [4] Additional Instrument Details - Other notable instruments include: - Vacuum interlinked electrical measurement system for semiconductor device analysis, budgeted at 3.8 million yuan - Mechanical thermal analyzer for measuring material properties, budgeted at 2 million yuan - High-power femtosecond laser system for precision machining applications, budgeted at 2.26 million yuan [5][6]

Core Viewpoint - Yunnan University has announced procurement intentions for 25 items of laboratory equipment, with a total budget of 169 million yuan, scheduled for procurement between February and May 2025 [1][2]. Procurement Overview - The procurement includes advanced instruments such as molecular interaction analyzers, multifunctional enzyme labelers, plasma focused ion beam cryo-electron microscopes, triple quadrupole liquid chromatography-mass spectrometry systems, and high-speed confocal microscopes [2][4]. - The total budget for these instruments is 169 million yuan, indicating a significant investment in research capabilities [1][2]. Specific Equipment and Budget - Molecular Interaction Analyzer: 1 set, unit price 3.1 million yuan [5]. - Multifunctional Enzyme Labeler: 1 set, unit price 1.46 million yuan [5]. - Plasma Focused Ion Beam Cryo-Electron Microscope: 1 set, unit price 20 million yuan [5]. - Triple Quadrupole Liquid Chromatography-Mass Spectrometry System: 1 set, unit price 3.3 million yuan [5]. - High-Speed Confocal Microscope: 1 set, unit price 3.9 million yuan [5]. Procurement Goals - The procurement aims to enhance research capabilities in various fields, including photovoltaic materials, electrochemical testing, and molecular biology, supporting the development of high-performance technologies [4][5]. - The equipment will facilitate comprehensive research processes from theoretical design to performance evaluation, particularly in the fields of materials science and life sciences [4][5]. Compliance and Standards - All procured equipment must meet national safety and environmental standards, ensuring compliance with mandatory energy-saving and environmental protection regulations [4][5][6].

Core Viewpoint - The article discusses the recent changes in the management and board of directors of Guangzhou Hexin Instrument Co., Ltd., including the election of a new chairman and the appointment of senior management personnel, amidst ongoing financial challenges faced by the company [1][2]. Board of Directors Election - On May 22, 2025, the company held its first meeting of the fourth board of directors, where it unanimously elected Mr. Zhou Zhen as the chairman of the board, with his term lasting until the end of the current board's term [4]. Special Committee Elections - During the same meeting, the company elected members and conveners for its special committees, including: - Audit Committee: Chaired by Chen Ming, with members Chen Ming, Zhou Zhen, and Liu Qiliang - Nomination Committee: Chaired by Liu Qiliang, with members Liu Qiliang, Kong Yunfei, and Zhou Zhen - Compensation and Assessment Committee: Chaired by Liu Qiliang, with members Liu Qiliang, Kong Yunfei, and Zhou Zhen - Strategic Development Committee: Chaired by Zhou Zhen, with members Zhou Zhen, Xu Xiangdong, and Liu Qiliang [6]. Senior Management Appointments - The board also approved the appointment of new senior management personnel: - Xu Xiangdong as General Manager - Sun Jiande as Chief Financial Officer - Lu Wanli as Secretary of the Board These appointments are effective from the date of the board's approval until the end of the current board's term [9]. Management Changes - The company has experienced multiple changes in its executive team since 2024, including the departure of several key executives, which may indicate instability within the management structure [11][20]. Financial Performance - In 2024, the company reported a significant decline in revenue, with total revenue of 203 million yuan, a decrease of 44.70% year-on-year. The net profit attributable to shareholders was a loss of approximately 46 million yuan, marking three consecutive years of losses, with total losses exceeding 200 million yuan [21][22]. - The company's R&D expenses also saw a substantial reduction of 51.44%, with R&D investment amounting to approximately 33 million yuan, representing only 16.20% of total revenue [22][23].

Core Viewpoint - JD.com is actively recruiting a head for its Cell Research Institute with a salary of one million, indicating its strategic focus on cell therapy as a significant breakthrough in the high-end medical services sector, with "cell storage" as a core business entry point [1][3][5]. Group 1 - The recruitment of a head for the Cell Research Institute has sparked discussions within the cell and gene therapy (CGT) industry [3]. - The job requirements highlight the need for experience in the commercialization of cell therapy products and practical experience with at least one CGT product's IND progress, suggesting JD.com's serious commitment to this field [5]. - JD.com has shown a strategic determination to deeply engage in the cell therapy sector, leveraging its strong financial resources, large user base, and e-commerce platform traffic to potentially disrupt traditional industry competition [8].

Core Viewpoint - Digital PCR technology is recognized as a revolutionary force in the field of molecular diagnostics, offering absolute quantification capabilities, high sensitivity, and specificity, which are essential for applications such as early cancer screening [1][3]. Group 1: Digital PCR Technology - Digital PCR is referred to as the third generation of PCR technology, showcasing significant advancements in automation and high-throughput detection efficiency [1]. - The technology is expected to provide reliable technical support for clinical applications, particularly in tumor early screening [1]. Group 2: Upcoming Conference - The "9th PCR Technology and Application Online Conference" will be held on May 28, 2025, organized by Instrument Information Network [3]. - The conference will feature various experts and scholars discussing the latest developments and innovative applications of digital PCR technology [1][3]. - A detailed agenda includes presentations on ultra-sensitive detection of low-frequency gene mutations, nucleic acid standard materials, and integrated high-sensitivity nucleic acid rapid detection technologies [3].